Pfizer Inc (PFE) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pfizer Inc. (PFE) has ended a Phase 1b trial titled “A Phase 1b, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Oral PF-07054894 in Adult Participants Aged 18-75 Years With Mild to Severe Ulcerative Colitis.” The study aimed to test safety and early benefit of PF-07054894 in ulcerative colitis, an area with steady long-term demand.
The main treatment was PF-07054894, an oral experimental drug. It was designed to reduce inflammation in the colon and offer a new option for patients who do not respond well to current therapies.
Participants were randomly assigned to receive either PF-07054894 or a placebo. The trial was double-blind, meaning neither patients nor study staff knew who got the real drug, and it was run in parallel groups with the main goal of treating symptoms.
The study was first submitted in September 2022 and targeted adults with mild to severe disease. It was later marked as terminated, and the record was last updated on February 24, 2026, signaling that no further dosing or follow-up in this protocol is planned.
For investors, the termination of this early-stage ulcerative colitis asset slightly trims Pfizer’s long-shot pipeline rather than its core earnings power. The chronic inflammatory bowel disease market remains competitive, with players like AbbVie and Johnson & Johnson still leading, so this update modestly lowers optionality for PFE rather than changing the sector outlook.
The study status is now listed as terminated and the record has been recently updated, with further details available on the ClinicalTrials portal.
To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.